Compare
Cero Therapeutics Holdings, Inc. vs enGene Therapeutics Inc. vs Tectonic Therapeutic, Inc. vs Allogene Therapeutics, Inc.
| Latest fiscal year | Cero Therapeutics Holdings, Inc. CERO | enGene Therapeutics Inc. ENGN | Tectonic Therapeutic, Inc. TECX | Allogene Therapeutics, Inc. ALLO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$19.92M | -$117.30M | -$74.15M | -$190.89M |
| EPS (Diluted) | n/a | $2.29 | -$4.05 | -$0.87 |
| Operating cash flow | -$16.10M | -$99.24M | -$60.08M | -$149.25M |
| Free cash flow | n/a | -$100.72M | -$60.29M | -$149.63M |
| Cash & equivalents | n/a | $50.15M | $253.80M | $51.69M |
| Total assets | $3.64M | $221.47M | $261.04M | $415.90M |
| Total liabilities | $9.09M | $53.76M | $9.71M | $123.36M |
| Shareholders' equity | -$5.45M | $167.71M | $251.33M | $292.54M |
| Return on year-end equity | n/a | -69.9% | -29.5% | -65.3% |
| Shares outstanding | n/a | 52.02M | 18.74M | 229.41M |
Revenue, most recent five fiscal years
| Fiscal year | Cero Therapeutics Holdings, Inc. | enGene Therapeutics Inc. | Tectonic Therapeutic, Inc. | Allogene Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $22.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $95.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $156.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $114.09M Ended 2021-12-31 |